Status:
RECRUITING
Decitabine Plus mBU/CY for High Risk Acute Leukemia With MRD Pre-HSCT
Lead Sponsor:
Peking University People's Hospital
Conditions:
Stem Cell Transplant Complications
Leukemia, Myeloid, Acute
Eligibility:
All Genders
18-55 years
Phase:
PHASE2
PHASE3
Brief Summary
Allogeneic haematopoietic stem cell transplantation (allo-HSCT) remains one of the currently available curative therapies for acute leukemia (AL). Leukemia relapse is one of the mainly causes of trans...
Detailed Description
Patients enrolled in this study would receive decitabine 200mg·m-2·d-1 on day -12 and -11 pre-HSCT. The conditioning therapy for human leukocyte antigen (HLA)-mismatched HSCT patients was modified BU/...
Eligibility Criteria
Inclusion
- acute leukemia patients with MLL-r,TLS-ERG,or SIL-TAL1,whose minimal residual disease were detectable pre-HSCT
Exclusion
- pregnancy women
- uncontrolled severe infection
Key Trial Info
Start Date :
September 1 2018
Trial Type :
INTERVENTIONAL
Allocation :
ESTIMATED
End Date :
October 1 2026
Estimated Enrollment :
55 Patients enrolled
Trial Details
Trial ID
NCT03793517
Start Date
September 1 2018
End Date
October 1 2026
Last Update
March 10 2020
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Peking University Institute of Hematology,Beijing
Beijing, Beijing Municipality, China, 100044